Aurobindo Pharma 's wholly owned subsidiary Eugia Pharma Specialities Limited has announced the commercial launch of pomalidomide capsules in the United States market. The company has launched the product in multiple strengths of 1 mg, 2 mg, 3 mg and 4 mg, marking a significant entry into the oncology segment.

Product Launch Details

The newly launched pomalidomide capsules serve as a generic equivalent of Pomalyst® Capsules of BMS Pharmaceuticals Corp. Eugia Pharma Specialities Limited was one of the First-to-File (FTF) ANDA applicants for this product, providing a competitive advantage in the market entry. The product will be manufactured at Eugia Unit-I facility.

Market Opportunity and Therapeutic Use

According to IQVIA MAT data for the twelve months ending January 2026, pomalidomide capsules have an estimated market size of approximately US$ 3.3 billion in the United States. This substantial market opportunity underscores the commercial potential for generic manufacturers entering this therapeutic space.

Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone and sometimes bortezomib to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. The availability of generic versions enhances treatment accessibility and provides cost-effective options for patients requiring this critical oncology medication.

Strategic Significance

This product launch strengthens Aurobindo Pharma's presence in the US pharmaceutical market through its subsidiary Eugia Pharma Specialities Limited. The First-to-File status provides competitive positioning in this high-value oncology segment. The introduction of pomalidomide capsules adds to the company's oncology portfolio, demonstrating continued commitment to developing and commercializing complex generic formulations in major global markets.

Aurobindo Pharma has issued an official clarification regarding the discharge of P Sarath Chandra Reddy, Non-Executive Director, in the Delhi Liquor Policy case. The Court of Sh. Jitendra Singh, Special Judge (PC Act) (CBI) -23, Rouse Avenue Court Complex, New Delhi discharged Reddy along with 22 other accused after extensive examination of evidence.

Court Ruling Details

The following table summarizes the key details of the court ruling:

Case Background and Charges

The case originated from FIR No. RC0032022A0053 lodged by CBI/ACB under multiple sections including 120-B, 420 and 201 of IPC and provisions of Section 7, 7A, 8 and 12 of the Prevention of Corruption Act, 1988. P Sarath Chandra Reddy was added as Accused No. 23 via the 4th supplementary chargesheet dated July 29, 2024.

Court's Findings

After thorough analysis of CBI allegations and material evidence, the court found no material evidence showing that P Sarath Chandra Reddy had:

• Participated in any conspiracy
• Influenced any public servant
• Paid or received any illegal gratification
• Obtained any unlawful benefit in relation to Delhi Liquor Policy

The court noted that it failed to comprehend the basis on which P Sarath Chandra Reddy was arrayed as an accused in the case.

Company's Official Response

Aurobindo Pharma issued the clarification pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in response to queries from NSE and BSE regarding media reports. The company confirmed that P Sarath Chandra Reddy has been discharged from the case in relation to all charges levelled by the CBI.